Manufacturing CAR-T cell therapies at scale: reducing cost of goods through innovative ancillary materials.

Claudia Zylberberg, PhD. CEO.

This presentation provides a view of the burgeoning cell and gene therapy sector through the lens of a leading ancillary materials manufacturer. It provides an overview of several critical components in the production of CAR-T therapies, and outlines the challenges associated with sourcing these materials at the quality system that regulatory agencies require while also containing the cost of goods sold (COGS), accelerating the commercialization of these life-saving advanced therapies.

Presentation: